Meeting
2020 ASCO Virtual Scientific Program
Outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) with brain metastases treated with pembrolizumab-based therapy.
Authors
Lova Sun
UPHS, Philadelphia, PA
Lova Sun , Christiana Davis , Melina Elpi Marmarelis , Seth Jeffries , Lydia Frenzel Sulyok , Wei-Ting Hwang , Aditi Puri Singh , Abigail T. Berman , Steven J. Feigenberg , William C. Levin , Joshua Bauml , Christine Agnes Ciunci , Roger B. Cohen , Corey J. Langer , Charu Aggarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9599)
DOI
10.1200/JCO.2020.38.15_suppl.9599
Abstract #
9599
Poster Bd #
365
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.
First Author: Luis G. Paz-Ares
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
First Author: Marina Chiara Garassino
Poster
2020 ASCO Virtual Scientific Program
A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).
First Author: Ferdinandos Skoulidis